Lawsuit filed for Investors who lost money with shares of Hims & Hers Health, Inc. (NYSE: HIMS)

An investor, who purchased shares of Hims & Hers Health, Inc. (NYSE: HIMS), filed a lawsuit over alleged violations of Federal Securities Laws by Hims & Hers Health, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Hims & Hers Health, Inc. (NYSE: HIMS) 25, 2025. NYSE: HIMS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

San Francisco, CA based Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. Hims & Hers Health, Inc. (NYSE: HIMS) reported that its annual Total Revenue rose from $872 million in 2023 to over $1.47 billion in 2024, and that its Net Loss of $23.54 million in 2023 turned into a Net Income of $126.03 million in 2024.

On April 29, 2025, Hims & Hers Health, Inc. (NYSE: HIMS) announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform."

On June 23, 2025, before the market opened, Novo Nordisk announced that it was terminating its partnership with Hims & Hers Health, Inc. (NYSE: HIMS), "based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk." The press release stated that Hims "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization.'" The press release further stated "[b]ased on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China" which "FDA has never authorized or approved" and which may contain "unsafe and illicit foreign ingredients."

Shares of Hims & Hers Health, Inc. (NYSE: HIMS) declined from $65.89 million on May 14, 2025, to as low as $40.88 per share on June 26, 2025.

The plaintiff claims that between April 29, 2025 and June 22, 2025, the Defendants failed to disclose to investors that Hims & Hers Health, Inc. was engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;", that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated, and that, as a result of the foregoing, the Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Hims & Hers Health, Inc. (NYSE: HIMS) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.